Bristol R&D Update: Apixaban Filing Delayed, Ipilimumab Approval Expected
This article was originally published in The Pink Sheet Daily
Executive Summary
Contrary to expectations, Bristol-Myers Squibb will not file early for a narrow indication of the novel anticoagulant apixaban.